New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 20, 2012
12:43 EDTMNTAMomenta Pharma petition for rehearing denied by Court of Appeals
Momenta Pharmaceuticals announced that the United States Court of Appeals for the Federal Circuit denied its request for a rehearing en banc to reconsider its three-judge panel opinion in the case of Momenta Pharmaceuticals vs. Amphastar Pharmaceuticals, Inc. The request for all active judges of the court to reconsider a panel decision, known as rehearing en banc, is only granted upon a majority vote. "We will continue to pursue our appellate options and we plan to file a petition for certiorari, asking the Supreme Court to review this case," said Craig Wheeler, president and CEO of Momenta.
News For MNTA From The Last 14 Days
Check below for free stories on MNTA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 15, 2014
10:36 EDTMNTAHigh option volume stocks
Subscribe for More Information
September 8, 2014
09:27 EDTMNTALeerink biotech analyst holds a luncheon meeting with a conference call
Biotech Analyst Schwartz provides an update on key trends and controversies for marketed MS therapies and discusses new data presented at ACTRIMS-ECTRIMS at a Luncheon Meeting with an Analyst/Industry conference call to be held in Boston on September 11 at 12:15 pm.
08:32 EDTMNTAMomenta Pharma exercises option to acquire antibody program from AnaptysBio
AnaptysBio announced that Momenta Pharma has exercised its option to acquire a novel antibody program from AnaptysBio. Upon payment of an option exercise fee to AnaptysBio, Momenta has received worldwide rights to therapeutic antibodies against a target selected based upon the anti-inflammatory effects of IVIg. The aforementioned option right was granted by AnaptysBio to Momenta under an agreement signed between the companies in December 2013.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use